99mTc-甲氧基异丁基异腈SPECT/CT检测肾嗜酸细胞瘤及其他良性肾病变的诊断准确性:系统评价与Meta分析
该系统评价与Meta分析纳入4篇文献共117个肾病变,评估99mTc-sestamibi SPECT/CT鉴别肾嗜酸细胞瘤与其他肾病变及与嫌色细胞癌的诊断准确性,汇总敏感度和特异度分别为92%和88%,结论认为该检查对良性及低级别肾病变具有高敏感度和特异度。
要点
- 所有报告研究均采用肿瘤与背景肾实质放射性摄取比值>0.6作为阳性标准。
- 99mTc-sestamibi SPECT/CT鉴别肾嗜酸细胞瘤与其他肾病变的汇总敏感度92%、特异度88%。
- 鉴别肾嗜酸细胞瘤与嫌色细胞癌的汇总敏感度89%、特异度67%。
核心结论
- 99mTc-sestamibi SPECT/CT对良性及低级别肾病变的定性具有高敏感度和特异度,可能有助于提高对考虑主动监测的不确定性肾肿块患者的诊断信心。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE、Scopus、Cochrane Library及灰色文献,纳入评估肾嗜酸细胞瘤与其他肾病变且以病理为参考标准、患者数>5例的原始研究。
- 共纳入4篇文献、117个肾病变,由两名评价者独立提取患者、临床、影像及性能参数,采用双变量混合效应回归模型进行Meta分析。
诊断标准与关键数值
- 99mTc-sestamibi SPECT/CT检测肾嗜酸细胞瘤与其他肾病变的汇总敏感度为92%(95%CI 72-98%)、特异度为88%(95%CI 79-94%)。
- 检测肾嗜酸细胞瘤与嫌色细胞癌的敏感度为89%、特异度为67%。
- 检测嗜酸细胞瘤-嫌色细胞癌谱系的特异度为96%(95%CI 84-99%)。
- 检测良性与其他恶性肾病变的敏感度为86%(95%CI 66-95%)、特异度为90%(95%CI 80-95%);当嗜酸细胞瘤被定性为良性时,敏感度为88%、特异度为95%。
- 所有报告研究均采用肿瘤与背景肾实质放射性摄取比值>0.6作为阳性研究的界值。
临床应用与阅片要点
- 在阅片和报告中,可将肿瘤与背景肾实质放射性摄取比值>0.6作为99mTc-sestamibi SPECT/CT判断阳性的参考界值,用于辅助鉴别肾嗜酸细胞瘤与其他肾病变。
- 该检查对良性及低级别肾病变具有高敏感度和特异度,可能有助于提高对考虑主动监测的不确定性肾肿块患者的诊断信心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The primary objectives of this systematic review and meta-analysis were to evaluate the diagnostic accuracy of 99mTc-sestamibi SPECT/CT for detecting renal oncocytoma versus (1) all other renal lesions and (2) chromophobe renal cell carcinoma (ChrRCC) alone.
METHODS: A systematic review of MEDLINE, EMBASE, Scopus, the Cochrane Library, and the Gray Literature was performed. Original articles with > 5 patients evaluating oncocytomas versus other renal lesions with SPECT/CT using a pathological reference standard were included. Patient, clinical, imaging, and performance parameters were independently acquired by two reviewers. Meta-analysis was performed using a bivariate mixed-effects regression model.
RESULTS: Four articles with a total of 117 renal lesions were included in analysis. The pooled and weighted sensitivity and specificity values of 99mTc-sestamibi SPECT/CT for detecting (1) renal oncocytoma versus other renal lesions were 92% (95% CI 72-98%) and 88% (95% CI 79-94%), respectively, and (2) 89% and 67%, respectively, for renal oncocytoma versus ChrRCC. The specificity for the detecting the oncocytoma-ChrRCC spectrum was 96% (95% CI 84-99%). The sensitivity and specificity for detecting benign versus malignant renal lesions were 86% (95% CI 66-95%) and 90% (95% CI 80-95%), and 88% and 95% when HOCTs were characterized as benign. All reporting studies used a cut-off tumor-to-background renal parenchyma radiotracer uptake ratio of > 0.6 for positive studies.
CONCLUSION: 99mTc-sestamibi SPECT/CT demonstrates a high sensitivity and specificity for characterizing benign and low-grade renal lesions. This test can help improve the diagnostic confidence for patients with indeterminate renal masses being considered for active surveillance.
引用
- Wilson MP, Katlariwala P, Murad MH, et al. Diagnostic accuracy of 99mTc-sestamibi SPECT/CT for detecting renal oncocytomas and other benign renal lesions: a systematic review and meta-analysis. Abdom Radiol (NY). 2020. PMID: 32193593. doi:10.1007/s00261-020-02469-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。